Literature DB >> 19922007

Toxicity of bisphosphonates.

Eric E Prommer1.   

Abstract

Bisphosphonates have become an important treatment for the palliation of metastatic bone disease. Their increasing use has lead to the recognition of toxicities that can lead to substantial morbidity for the patient with advanced cancer. This case presentation highlights toxicities associated with bisphosphonate use and provides some guidelines on the use of bisphosphonates and management of these toxicities.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19922007     DOI： 10.1089/jpm.2009.9936

Source DB:  PubMed          Journal:  J Palliat Med        ISSN： 1557-7740            Impact factor:   2.947


  8 in total

1.  Vertebral compression fractures during chemotherapy for childhood acute lymphoblastic leukemia: commentary on a report from the STeroid Associated Osteoporosis in the Pediatric Population (STOPP) research program.

Authors:  Kirsten K Ness; Wassim Chemaitilly; Sue C Kaste
Journal:  Transl Pediatr       Date:  2012-10

Review 2.  Targeting polymer therapeutics to bone.

Authors:  Stewart A Low; Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-01-28       Impact factor: 15.470

Review 3.  Side effects of bone-targeted therapies in advanced breast cancer.

Authors:  Christoph Domschke; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

4.  Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.

Authors:  Ehud Segal; Huaizhong Pan; Liat Benayoun; Pavla Kopečková; Yuval Shaked; Jindřich Kopeček; Ronit Satchi-Fainaro
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

Review 5.  Management of pain in the elderly at the end of life.

Authors:  Eric Prommer; Brandy Ficek
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

6.  Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data.

Authors:  Christopher Kim; Rohini K Hernandez; Lori Cyprien; Alexander Liede; Paul C Cheng
Journal:  Support Care Cancer       Date:  2018-03-07       Impact factor: 3.603

7.  Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.

Authors:  Alexandra von Au; Eva Milloth; Ingo Diel; Stefan Stefanovic; Andre Hennigs; Markus Wallwiener; Joerg Heil; Michael Golatta; Joachim Rom; Christof Sohn; Andreas Schneeweiss; Florian Schuetz; Christoph Domschke
Journal:  Onco Targets Ther       Date:  2016-07-08       Impact factor: 4.147

Review 8.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.